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Abstract
Cancer is a common cause of death in the United States and locally in the state of Arkansas.
Modifiable factors such as tobacco use, physical activity, and diet lead to reduced incidence of
colon cancer diagnosis. Fruits and vegetables contain phytochemicals that confer health
promoting properties. Specifically, peanuts contain phytochemicals known as resveratrol,
arachidin-1, and arachidin-3 that have been linked to anticancer activities. However, a few
research studies have been done on arachidin-1 and arachidin-3 that could further develop
understanding of their health promoting properties or nutraceutical applications. The objectives
of this study were to (1) determine the most effective concentration of arachidin-1 and arachidin3 for inhibiting cell proliferation and (2) to assess the bioavailability of these compounds.
Concentrations of 0, 5, 10, and 20 µM arachidin-1 and arachidin-3 were applied and cell viability
was measured at 0, 24, and 48 hours. Significant reduction of cell proliferation occurred with
treatments of 10 and 20 µM arachidin-1 and 10 and 20 µM arachidin-3 in comparison with the
control. Due to the limit of HPLC detection, no transport values were determined when
arachidin-1 and arachidin-3 were applied in 50 and 100 µM concentrations. The findings suggest
that arachidin-1 and arachidin-3 inhibit cell proliferation in human colon cancer cells. Further
research is needed to understand the bioavailability of arachidin-1 and arachidin-3.
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Introduction
Cancer is one of the leading causes of mortality in the state of Arkansas and around the
United States. Specifically, an incidence rate of 50.1% per 100,000 for males and 37% per
100,000 for females exists for colon cancer in the state of Arkansas (American Cancer Society,
2017). The mortality rate for colon cancer in Arkansas is approximately 18.2% per 100,000
people, which ranks third highest compared with other states in the United States (National
Cancer Institute, 2015).
Genetic and lifestyle factors are potentially influential in the development of colon cancer
(Burt et al., 2010). Prevention is important in reducing incidence and mortality rates associated
with colon cancer (American Cancer Society, 2016). Amin et al. (2009) reported an inverse
relationship between a diet rich in fruits and vegetables and diagnosis with colon cancer. This
relationship can be attributed to the phytochemicals found in fruits and vegetables (Amin et al.,
2009). The peanut plant (Arachis hypogaea L.) is a source of phytochemicals known as
stilbenoids, which confer cancer preventative properties following extraction from the root or
kernel of the peanut plant. Arachidin-1, arachidin-3, and resveratrol are stilbenoids derived from
the peanut plant (Huang et al., 2010). While a significant amount of research has been conducted
involving resveratrol, there is limited information available about the health-promoting
properties of arachidin-1 and arachidin-3 (Chang et al., 2006).
Understanding the bioavailability of phytochemicals is essential for determining their
biological and health effects in humans. Therefore, the objectives of the present study were to: 1)
determine the effective concentrations of arachidin-1 and arachidin-3 for inhibiting colon cancer
cell growth, and 2) assess the intestinal transport of arachidin-1 and arachidin-3 to determine
which compound is more bioavailable.
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Literature Review
Colorectal Cancer
Cancer remains the second leading cause of death in the United States with a mortality
rate of 22.9% (Heron, 2015). Mortality rates related to cancer vary among people of different
age, sex, and racial backgrounds (Heron, 2015). A study conducted by Moghaddam et al. (2007)
reported that cancer of the colon and rectum contributes to a major portion of the morbidity and
mortality occurring globally. Colon and rectum cancer is projected as the third leading type of
cancer for estimated new cases and estimated deaths in 2017 (Figure 1, American Cancer
Society, 2017).

Figure 1. 2017 Estimation of Leading Cancer Sites. (American Cancer Society, 2017)
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Several factors can influence the development of colorectal cancer. In fact, 30% of
colorectal cancer cases stem from mutated genes predisposing individuals for development of the
disease. These mutations are diagnosed through genetic testing. Genetic factors may be
especially influential in the development of colon cancer if the individual has Lynch syndrome,
familial adenomatous polyposis, or several other genetic conditions (Burt et al., 2010).
Additional factors affecting colorectal cancer incidence rates include Type II diabetes and a
family history of colon cancer (American Cancer Society, 2016).
About 70% of colorectal cancer cases are influenced by major lifestyle factors such as
overweight/obesity, physical activity, alcohol consumption, tobacco use, and diet (American
Cancer Society, 2016; Burt et al., 2010). These factors can be controlled by the lifestyle choices
that individuals make (American Cancer Society, 2016). Precautionary measures such as regular
health screenings in addition to consumption of a healthy diet for prevention of obesity can
reduce colorectal incidence rates (American Cancer Society, 2016). Overweight or obesity
resulting from lack of balance between nutritional intake and physical activity leading to excess
weight increases the risk for colorectal cancer. An individual with obesity possesses a risk of
20% greater for developing colorectal cancer than individuals of normal weight (Moghaddam et
al., 2007).
Epidemiological studies indicate that diet has implications on the incidence of colorectal
cancer (Birt and Philips, 2014; Chan and Giovannucci, 2010; Chen et al., 2015; Kim and Milner,
2007). Diets characterized by large quantities of red meat, alcohol, simple sugars and refined
grains are associated with obesity and higher incidence of colorectal cancer (Chen et al., 2015).
Conversely, a diet consisting of vegetables, fiber, legumes, whole grains, poultry, fish, and a low
amount of dietary fat is associated with lower incidence of colorectal cancer (Chan and
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Giovannucci, 2010). Phytochemicals found in fruits and vegetables hold potential for prevention
of cancer due to antioxidant activity (Amin et al., 2009).

Phytochemicals in the Peanut Plant
Chemical Structure of Resveratrol, Arachidin-1, and Arachidin-3
Phytochemicals such as resveratrol (trans-3,5,4’- trihydroxystilbene), arachidin-1 [trans-4-(3methyl-1-butenyl)-3,5,3’,4’-tetrahydroxysilbene)], and arachidin-3 [trans-4-(3-methyl-1-butenyl)-3,5,4’trihydroxystilbene)] are stilbenoids derived from the peanut plant. Each of these phytochemicals

have similar chemical structures. Arachidin-1 and arachidin-3 are the prenylated analogs of
resveratrol. Figure 2 demonstrates the structural similarities of these compounds.

Figure 2. Chemical Structures of Resveratrol, Arachidin-1, and Arachidin-3. (Ball et al., 2015.)

ANTI-CANCER AND BIOAVAILABILITY OF ARACHIDIN-1 AND ARACHIDIN-3

9

Concentrations of Resveratrol, Arachidin-1, and Arachidin-3 in the Peanut
Resveratrol is found in various parts of the peanut plant in addition to being available in
processed foods (Chang et al., 2006). Resveratrol in peanuts prepared by boiling contains 5.1 µg
resveratrol per gram of boiled peanut while peanut butter contains 0.3 µg resveratrol per gram.
No studies have detected arachidin-1 and arachidin-3 in peanuts. However, arachidin-1 and
arachidin-3 are obtained for research purposes via extraction and purification from seeds and
roots of the peanut plant, and range from 0.4 to 5.7 nmol/g dry weight (Condori et al., 2010).

Health Effects of Phytochemicals in the Peanut
Anti-Inflammatory Properties
Antioxidant activity of resveratrol has been widely investigated. This stilbenoid has been
linked to anti-inflammatory effects through in-vitro cell study (Chang et al., 2006; Djoko et al.,
2007; Huang et al., 2010). In a particular study, 15 µM arachidin-1, 15 µM arachidin-3, and 15
µM resveratrol were applied to RAW 264.7 mouse macrophage cells to cause inhibition of LPS
(lipopolysaccharide)-induced responses (Chang et al., 2006). Macrophage cells are essential for
inflammation, infection, and immune response. LPS results in activation of macrophage cells to
secrete inflammatory responses such as prostaglandins (PGs) and nitric oxide (NO). The
production of these mediators is associated with inflammation within the cell. Application of all
three stilbenoids to RAW 264.7 macrophage cells resulted in reduced inflammation activity. Of
the three, resveratrol yielded the greatest anti-inflammatory effect. Arachidin-1 yielded greater
anti-inflammatory effects than arachidin-3 (Chang et al., 2006).
Nuclear factor kappa B (NF-𝜅B) is a heterodimeric protein consisting of different
combinations of transcription factors. NF- 𝜅B plays a major role in regulating transcription of
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genes for cytokine production and cell survival. Activation of NF- 𝜅B is associated with
inflammation, cancer, and autoimmune diseases (Badr et al., 2009).
In a study conducted by Djoko et al. (2007), stilbenoids of similar structure including
arachidin-1, piceatannol, and resveratrol were investigated for the reduction of inflammatory
effects in RAW 264.7 mouse macrophage cells. The inhibition of LPS-induced NO and PGE2
production was evaluated to determine their role in immune functions. The NF-𝜅B activity
leading to inflammatory gene expression was also monitored (Djoko et al., 2007). The treatment
of stilbenoids including resveratrol, piceatannol, and arachidin-1 correlates with reduced NF- 𝜅B
activity in RAW 264.7 macrophage cells. All three compounds inhibited productions of PGE2
and NO in a dose-dependent manner. Arachidin-1 and resveratrol were applied in concentrations
of 3.75, 7.50, 15.0, and 30.0 µM while piceatannol was applied at 1.88, 3.75, 7.5, and 15 µM
concentrations. Application of arachidin-1, resveratrol, and piceatannol resulted in reduced
inflammation responses. This study indicates that these derivatives have potential to contribute to
nutraceutical applications by providing anti-inflammatory effects (Djoko et al., 2007). More
research is needed to further determine the anti-inflammatory effects of prenylated stilbenoids
(arachidin-1 and arachidin-3) since these derivatives have been less researched.
Anti-Cancer Properties of Phytochemicals
Excluding resveratrol, anticancer properties of stilbenoids have been minimally
investigated. However, in the studies that have been done, resveratrol, arachidin-1, and
arachidin-3 have also been linked to anti-cancer properties (Huang et al., 2010; Amin et al.,
2009; Ko et al., 2013; Ball et al., 2015). Resveratrol and arachidin-1 induce anticancer activity
by causing programmed cell-death or apoptosis in human leukemia HL-60 cells (Huang et al.,
2010). Arachidin-1 was more effective than resveratrol for inducing programmed cell-death
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(PCD) when both compounds were applied in concentrations of 0-20 µM. Optimal
concentrations for achieving cell death were 4.2 and 17.6 µM, respectively, for arachidin-1 and
resveratrol. Programmed cell-death is essential for maintaining equilibrium in cell division
patterns. This occurs because caspase-independent pathways are activated in the process of PCD
and these pathways lead to apoptosis when cells contain mutations in apoptotic genes (Huang et
al., 2010). Apoptosis is important in eliminating mutated cells that can lead to the development
of cancer (Badr et al., 2009). Cell exposure to arachidin-1 caused PCD to occur more efficiently
than resveratrol due to activation of both caspase-dependent and caspase-independent pathways
(Huang et al., 2010).
The results reported in Athar et al. (2009) support that resveratrol suppresses cancer cell
growth by influencing cell cycle kinase activity and accumulation of p53 in cells. Cell cycle
kinases are involved in the development of colorectal cancer and leukemia by phosphorylating
receptors on the cell to affect tumorigenesis. Resveratrol stops transition between cell cycle
phases so that cells with mutated DNA either cannot double their DNA or divide (Athar et al.,
2009). Resveratrol also increases p53 levels and decreases Bcl-2 levels. P53 is a transcription
factor that functions as a tumor suppressor gene and monitors for mutations. Bcl-2 is an antiapoptosis protein that is expressed less frequently with increased p53 levels present in a cell. As
a result, high levels of p53 and low levels of Bcl-2 resulting from exposure of cells to resveratrol
can lead to apoptosis of cancer cells (Athar et al., 2009). Since arachidin-1 and other stilbenoids
are similar in structure to resveratrol, these stilbenoids have the potential to confer anticancer
properties. It is necessary to further investigate the specific roles of arachidin-1 and arachidin-3
in anticancer effects.

ANTI-CANCER AND BIOAVAILABILITY OF ARACHIDIN-1 AND ARACHIDIN-3

12

Bioavailability of Phytochemicals in Peanut Plant
Bioavailability refers to the rate at which a nutrient is sent to the bloodstream for use in
the body (Parada and Aguilera, 2007). Chukwumah et al. (2011) evaluated the transport and
absorption of trans-resveratrol using a Caco-2 cell monolayer. The preparation of the peanut
derivative impacts the rate of transport, or bioavailability. A study examining bioavailability of
trans-resveratrol used different preparation methods including boiling and roasting the peanuts.
Roasted peanuts yielded better transport ability for trans-resveratrol than boiled peanuts
(Chukwumah et al., 2011).
Bioavailability studies on arachidin-1 and arachidin-3 are not available. However, a
strong understanding of bioavailability for arachidin-1 and arachidin-3 is necessary so that
knowledge of biological activity by the compounds are available.
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Materials and Methods
Materials
Arachidin-1 and arachidin-3 were generously donated by Dr. Medina-Bolivar in their
pure form (Arkansas State University, Jonesboro, AR). All reagents and media components were
purchased from ThermoFisher (Waltham, MA).

Methods
HPLC Analysis
To measure arachidin-1 and arachidin-3, a System Gold high performance liquid
chromatograph (Beckman-Coulter, Fullerton, CA, USA) with autosampler (model 508), dual
pump (model 126), photodiode array detector (model 168) with Beckman-Coulter System 32
Karat software (version 8, 2006) was used. Arachidin-1 and arachidin-3 were separated using the
method proposed by Abbott et al. (2010) to ensure the compounds being used for the study were
pure. Separation of the phytochemicals occurred with the Phenomenex (Torrance, CA) Aqua 5
µM C18 (250 x 4.6 mm) column containing a binary gradient of 2% formic acid [mobile phase
A] and 99:1 (v/v) acetonitrile/mobile phase A [mobile phase B]. The gradient began with 10% B
and increased uniformly to 18% for approximately 8 minutes. The gradient was then held at 18%
B for 2 minutes before increasing linearly to 25% B over the course of 5 minutes, and increasing
to 35% B for 3 minutes. Then the gradient remained isocratic or constant and uniform in the
mobile phase for 20 minutes at 35%. B increased uniformly to 60% over the course of 59
minutes before returning to the initial binary gradient of 10%. The peaks of arachidin-1 and
arachidin-3 were monitored at 340 nm.
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Cell Culture
Caco-2 cells, a human epithelial colorectal adenocarcinoma cell line, purchased from
American Type Culture collection (ATCC, Rockville, MD) were incubated at 37°C in an
atmosphere containing 5% 𝐶𝑂2. Cells were cultivated in Dulbecco’s Modified Eagle’s Medium
(DMEM) with 10% fetal bovine serum (FBS), 1 % nonessential amino acids solution, and 1%
antibiotic-antimycotic. Cell cultures were maintained under sterile conditions and incubated at
37°C, 70% humidity, and 5% CO2 in the incubator (VWR® symphony™, VWR® International
LLC, Radnor, PA).

Cell Viability Assay
Caco-2 cells, passage number 36-42, were used for the viability assay. For a standard
curve, cells attached to the chambers of a 96-well microplate (Corning Inc., Tewksbury, MA) for
24 hours after being seeded in a range from 0 to 3.2x103 cells with 100 µL working media
(WMEM). For the experiment, cells (2 x 103) were seeded in wells of a 96 well plate for 24
hours. Three separate plates were prepared for each experiment. A total of five experiments were
performed over the course of this study. At the end of the 24 hour period, the media was
aspirated and then cells were treated with 100 µL of 0, 5, 10, or 20 µM concentration of
arachidin-1 or arachidin-3. These concentrations were chosen based off of results from previous
studies evaluating cell viability. Dried arachidin-1 or arachidin-3 was suspended in DMEM in
the quantity deemed calculated when the density was converted to moles. The compounds were
then suspended in media to make a 100 µM stock solution and then dilutions with media were
made accordingly. Each treatment was applied in quadruplicate. The control was treated with
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100 µL of 0.1% DMSO. Measurements were obtained at 0 (T0), 24 (T24), and 48 (T48) hours
following treatment in order to determine cell viability. When the absorbance was read at T0T48, 20 µL of cell titer reagent (CellTiter96® Aqueous One Solution Proliferation Assay,
Promega Co., Madison, WI) was added to each well. Using a plate reader (Synergy HT MultiMode Microplate Reader, BioTek Instruments, Inc. Winooski, VT) the absorbance of the cells
were measured at 490nm. This absorbance was converted to the number of viable cells using an
equation from the standard curve. Based on the number of viable cells present at T0, a
proliferation percentage was calculated for T24 and T48.

Intestinal Transport Assay
Caco-2 cells were seeded at a density of 1 x 105 /cm2 cells on polycarbonate membrane
inserts (12 mm diameter, pore size 0.4 µM) fitted in bicameral chambers (Corning Inc.,
Tewksbury, MA). Cell monolayer integrity was confirmed by determining the transepithelial
electrical resistance (TEER) values using the Millicell ERS-2 Voltohmmeter (EMD Millipore,
Billerica, MA). After seeding, media was aspirated from both the apical and basal chambers. 1
mL of PBS was added to the basal chamber and 0.5 mL of 50 and 100 µM arachidin-1 or
arachidin-3 was added to the apical chamber.
For time 0h, transport media containing arachidin-1 (or arachidin-3) was loaded and 0.5
mL of PBS were collected immediately in a vial. Each vial is preserved with 25 µL
trifluoroacetic acid (TFA) and 25 µL 70% ethanol. At this point, 0.5 mL of PBS was replaced in
the basal chamber. The plate was incubated at 37°C for 30 minutes. For time 0.5h and time 1h,
steps performed for time 0 were repeated. The plate was incubated for 1 hour following time 1.
At the end of 2 hours, media from the apical was collected in a vial and rinsed with 0.5 mL of
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PBS three times. PBS was removed from the basal chamber, collected in a vial, and rinsed with 1
mL of PBS. Each vial was preserved with 25 µL TFA and 25 µL 70% ethanol. All aliquots were
frozen at -20°C until analysis via HPLC. Apparent permeability coefficients (Papp) was calculated
using the following equation:

Where dQ/dt is the rate of permeation across the cell, A is the area of the cell monolayer, and C0
is the initial concentration of the apical chamber.

Statistical Analysis
All statistical analyses were carried out by JMP software (version 13; SAS Institute Inc.,
Cary, NC) using a one-way analysis of variance test (ANOVA). ANOVA results were compared
with the student’s t test. Data was represented as means ± standard error of mean (SEM).
Statistically significance was accepted at P<0.05.
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Results
Identification of Arachidin-1 and Arachidin-3
Arachidin-1 and arachidin-3 used for this experiment were identified as pure compounds
at 304 nm. The results are shown in Figure 3.

Absorbance (nm)

Arachidin-3

Arachidin-1

Time (min)

Figure 3. High Performance Liquid Chromatogram of arachidin-1 and arachidin-3 at 340 nm.

Cell Viability after Arachidin-1 and Arachidin-3 Treatment
The data presented in Figures 4 and 5 shows that arachidin-1 and arachidin-3 treatments
(10 µM and 20 µM) reduced cell viability compared to control.
At the 48 hour time point, 10, and 20 µM concentrations of arachidin-1 resulted in a
significant reduction of cell viability (%) compared to the control (P<0.05) (Figure 4). There was
no significant difference of cell viability between treatments and control at time point 24 hours.
The cell viability was significantly reduced in treatments of 10 and 20 µM arachidin-3
compared to 5 µM arachidin-3 and the control at time point 48 hours (P<0.05) (Figure 5).
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Figure 4. Effect of arachidin-1 on the survival of Caco-2 cells. Values with different letters at
the same incubation time are significantly different (P<0.05).
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Figure 5. Effect of arachidin-3 on the survival of Caco-2 cells. Values with different letters at
the same incubation time are significantly different (P<0.05).
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At time point 48 hours, 10 and 20 µM concentrations of arachidin-1 showed the lowest
cell viability in comparison with cell viability measured after treatments of 10, or 20 µM
arachidin-3 or control (P<0.05).
300

a

T0

T24

T48

a

% Proliferation

250

b

b

b

200

c

c

10 Ara-1

20 Ara-1

150

100

50

0

control

5 Ara-1

5 Ara-3

10 Ara-3

20 Ara-3

Figure 6. Summarized effects of arachidin-1 and arachidin-3 on the survival of Caco-2 cells.
Values with different letters at the same incubation time are significantly different (P<0.05).

Intestinal Transport Assay of Arachidin-1 and Arachidin-3 Treatment
Arachidin-1 was not detected in samples from both apical and basal chambers treated
with 50 µM or 100 µM at time point 2 hr (Figure 7). At time point 2 hr, a trace amount of
arachidin-3 was detected in apical sample treated with 100 µM (Figure 8). Apparent permeability
coefficient (Papp) values of arachidin-1 and archidin-3 were not determined.
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Figure 7. HPLC Chromatogram of (A) arachidin-1 standard, (B) apical sample treated with 100
µM of arachidin-1 and (C) basal sample treated with 100 µM of arachidin-1 at time point 2 hr.
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Figure 8. HPLC Chromatogram of (A) arachidin-3 standard, (B) apical sample treated with 100
µM of arachidin-3 and (C) basal sample treated with 100 µM of arachidin-3 at time point 2 hr.
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Discussion
The peanut root contains phytochemicals that confer anticancer and anti-inflammatory
effects to the body for a nutraceutical approach. Arachidin-1 and arachidin-3, derivatives from
the peanut plant, have been involved in limited research relating to their health effects in the
body for cancer prevention. Therefore, the anti-colon cancer activity and bioavailability of
arachidin-1 and archidin-3 have been investigated in this study.
In order to understand the anticancer properties linked with arachidin-1 and arachidin-3,
it is important to evaluate the effect of these compounds on colon cancer cell proliferation. In the
present study, both arachidin-1 and arachidin-3 treatments (10 and 20 µM) resulted in reduced
cell proliferation rates compared with the control (P<0.05). The most significant reduction of cell
proliferation occurred at time point 48 hours when arachidin-1 was applied at concentrations of
10 and 20 µM in comparison with the control or 5, 10, and 20 µM arachidin-3 treatments
(P<0.05).
The limited studies have investigated the anticancer properties of arachidin-1 and
arachidin-3 in different cell lines with different concentrations of stilbenoids (Huang et al., 2010;
Ko et al., 2013; Ball et al., 2015). Cell viability results from a study on the effect of 0 to 20 µM
concentrations of arachidin-1, arachidin-3, and resveratrol on human leukemia cell (HL-60)
proliferation reported that arachidin-1 resulted in reduced cell viability (Huang et al., 2010).
Another study investigated the effects of metformin and arachidin-1 upon dose-dependent
application to A549 and H1975 human lung cancer cell lines. Metformin is an anti-diabetic drug
that is associated with anticancer properties. Treatments of 0.5, 1, 5, and 10 µM arachidin-1 with
25 µM metformin over the course of a 4-day incubation period resulted in reduced cell viability.
(Ko et al., 2013).
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10 and 20 µM concentrations of arachidin-1, resveratrol, piceatannol, and arachidin-3
were applied to rotavirus infected HT29.F8 cells from the human adenocarcinoma line of the
intestine. These concentrations of stilbenoids did not result in a substantial decrease in cell
viability. However, application of arachidin-1 or arachidin-3 resulted in reduced viral replication
and can be attributed to antioxidant activity of these compounds (Ball et al., 2015). Additional
research must be conducted to understand the effects of stilbenoids from the peanut plant on cell
viability.
Previous studies regarding the transport abilities of arachidin-1 and arachidin-3 have not
been conducted. Due to the limit of detection in the HPLC system, the apparent transport of
arachidin-1 and arachidin-3 were not calculated. Additional research must be conducted with
higher concentrations of arachidin-1 and arachidin-3 in order to evaluate bioavailability.
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Conclusions
The results of this study indicate that concentrations greater than 10 µM arachidin-1 and
arachidin-3 did reduce cell viability in human colon cancer cells in comparison with the control.
Arachidin-1 was more effective for inhibiting cell proliferation than arachidin-3. No apparent
intestinal transport occurred, so it is likely that concentrations of arachidin-1 and arachidin-3
greater than 100 µM are needed to determine bioavailability. Additional research is needed to
establish the chemopreventative or nutraceutical applications of arachidin-1 and arachidin-3.
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